Myomo (MYO) risk factors

60 risks, 7 new, 4 dropped, 19 reworded since the prior year. Operating losses worsened significantly to $15.6 million in 2025, driven by higher R&D and advertising costs. New debt covenants with Avenue restrict operations and require maintaining $2.5 million in cash. Medicare Advantage authorizations declined, and social media algorithm changes increased lead generation costs.

57 risks. Myomo faces ongoing operating losses with an accumulated deficit of $103.1 million, while relying heavily on direct billing and Medicare Advantage reimbursement for its MyoPro device.